Brief: Hyloris: Commercial Partnership For Maxigesic® ® IV In 9 European Countries

Hyloris Pharmaceuticals SA

24/01/2023 06:03

Jan 24 (Reuters) - Hyloris Pharmaceuticals SA  HYL.BR :
    * HYLORIS ANNOUNCES COMMERCIAL PARTNERSHIP FOR MAXIGESIC® IV
IN 9
EUROPEAN COUNTRIES
    * EXCLUSIVE LICENSING AND DISTRIBUTION AGREEMENT SIGNED WITH
SALUS
PHARMACEUTICALS IN LITHUANIA, ESTONIA, LATVIA, CROATIA,
SLOVENIA, SERBIA, NORTH MACEDONIA, MONTENEGRO AND BOSNIA
    * FIRST COMMERCIAL LAUNCHES PLANNED LATER THIS YEAR
    * HAS SIGNED AN EXCLUSIVE LICENSING AND DISTRIBUTION
AGREEMENT
WITH SALUS PHARMACEUTICALS FOR MAXIGESIC® IV, A NOVEL, DUAL
MODE-OF-ACTION NON-OPIOID PAIN TREATMENT DELIVERED THROUGH
INTRAVENOUS (IV) INFUSION, IN 9 EUROPEAN MARKETS
    * UNDER TERMS OF DEVELOPMENT COLLABORATION AGREEMENT BETWEEN
HYLORIS AND AFT, HYLORIS IS ELIGIBLE TO RECEIVE A SHARE ON ANY
PRODUCT-RELATED REVENUES, SUCH AS LICENSE FEES, ROYALTIES,
MILESTONE PAYMENTS, RECEIVED BY AFT
    * AGREEMENT WITH SALUS PHARMACEUTICALS ENCOMPASSES FOLLOWING
EUROPEAN TERRITORIES: LITHUANIA, ESTONIA, LATVIA, CROATIA,
SLOVENIA, SERBIA, NORTH MACEDONIA, MONTENEGRO, AND BOSNIA
    * MAXIGESIC® IV IS ALREADY REGISTERED IN LITHUANIA, ESTONIA,
LATVIA, CROATIA AND SLOVENIA, WHERE FIRST COMMERCIAL LAUNCHES
ARE EXPECTED LATER THIS YEAR. REGISTRATION APPLICATIONS WILL BE
FILED IN REMAINING COUNTRIES (SERBIA, NORTH MACEDONIA,
MONTENEGRO, BOSNIA)

Source text for Eikon:  ID:nGNE9slKvz 
Further company coverage:  HYL.BR 
 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))